If you would like to earn credit, you must take the pre-test first by clicking here.

This activity was supported by educational grants from Bristol-Myers Squibb Company; Genomic Health, Inc.; and Merck Sharp & Dohme Corp.

Precision Oncology Comes of Age: Tumor-Agnostic Approaches

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA
Winship Cancer Institute of Emory University

Colleen Lewis, MSN, ANP-BC, AOCNP
Winship Cancer Institute of Emory University

Guided by two experts in the field, dive into the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support the advancement of precision medicine.


Download Slides


These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.